Evidence map›Paper›PMID 24762744›Full record

ArticlePLoS neglected tropical diseases2014

Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults.

Mohammad Murshid Alam, Amena Aktar, Sadia Afrin, Mohammad Arif Rahman, Sarmin Aktar, Taher Uddin, M Arifur Rahman, Deena Al Mahbuba, Fahima Chowdhury, Ashraful Islam Khan and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Confronting challenges to enterotoxigenicFrontiers in tropical diseases · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Development of an enterotoxigenicHuman vaccines & immunotherapeutics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 3 countries.

Mohammad Murshid AlamCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Amena AktarCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Sadia AfrinCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Mohammad Arif RahmanCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Sarmin AktarCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Taher UddinCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
M Arifur RahmanCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Deena Al MahbubaCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Fahima ChowdhuryCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Ashraful Islam KhanCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Taufiqur Rahman BhuiyanCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Yasmin Ara BegumCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Edward T RyanDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Stephen B CalderwoodDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Ann-Mari SvennerholmGothenburg University Vaccine Research Institute (GUVAX), Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.
Firdausi QadriCentre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
International Centre for Diarrhoeal Disease Research · BDMassachusetts General Hospital · USUniversity of Gothenburg · SE

Funding

Protecutive immunity to human cholera in BangladeshU01AI058935 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CALDERWOOD, STEPHEN B., RYAN, EDWARD T. · 2003 to 2014
$7.8M
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine developmentU01AI077883 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2008 to 2012
$5.6M
Training program in vaccine development and public healthD43TW005572 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI QADRI, FIRDAUSI, RYAN, EDWARD T. · 2000 to 2025
$5.4M
O-Specific Polysaccharide Responses and CholeraR37AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Edward T. Ryan · 2020 to 2026
$5.1M
O-Specific Polysaccharide Responses and CholeraR01AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2014 to 2018
$3.7M
O-Specific Polysaccharide Responses and CholeraR56AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2013 to 2020
$843k
FIC NIH HHS D43 TW005572FIC NIH HHS TW005572NIAID NIH HHS AI058935NIAID NIH HHS AI077883NIAID NIH HHS AI106878NIAID NIH HHS R01 AI106878NIAID NIH HHS R37 AI106878NIAID NIH HHS R56 AI106878NIAID NIH HHS U01 AI058935NIAID NIH HHS U01 AI077883
6 · The paper itself

Abstract

backgroundMultiple infections with diverse enterotoxigenic E. coli (ETEC) strains lead to broad spectrum protection against ETEC diarrhea. However, the precise mechanism of protection against ETEC infection is still unknown. Therefore, memory B cell responses and affinity maturation of antibodies to the specific ETEC antigens might be important to understand the mechanism of protection. METHODOLOGY: In this study, we investigated the heat labile toxin B subunit (LTB) and colonization factor antigens (CFA/I and CS6) specific IgA and IgG memory B cell responses in Bangladeshi adults (n = 52) who were infected with ETEC. We also investigated the avidity of IgA and IgG antibodies that developed after infection to these antigens. PRINCIPAL

findingsPatients infected with ETEC expressing LT or LT+heat stable toxin (ST) and CFA/I group or CS6 colonization factors developed LTB, CFA/I or CS6 specific memory B cell responses at day 30 after infection. Similarly, these patients developed high avidity IgA and IgG antibodies to LTB, CFA/I or CS6 at day 7 that remained significantly elevated at day 30 when compared to the avidity of these specific antibodies at the acute stage of infection (day 2). The memory B cell responses, antibody avidity and other immune responses to CFA/I not only developed in patients infected with ETEC expressing CFA/I but also in those infected with ETEC expressing CFA/I cross-reacting epitopes. We also detected a significant positive correlation of LTB, CFA/I and CS6 specific memory B cell responses with the corresponding increase in antibody avidity.

conclusionThis study demonstrates that natural infection with ETEC induces memory B cells and high avidity antibodies to LTB and colonization factor CFA/I and CS6 antigens that could mediate anamnestic responses on re-exposure to ETEC and may help in understanding the requirements to design an effective vaccination strategies.

Indexed as

Immunologic MemoryAdultAntibodies, BacterialAntibody AffinityAntigens, BacterialBacterial ToxinsBangladeshB-LymphocytesEnterotoxigenic Escherichia coliEnterotoxinsEscherichia coli InfectionsEscherichia coli ProteinsFemaleFimbriae ProteinsHumansImmunoglobulin AAntibodies, BacterialAntigens, BacterialBacterial ToxinsCS6 antigen, E coliEnterotoxinsEscherichia coli ProteinsFimbriae Proteinsheat-labile enterotoxin, E coliImmunoglobulin AImmunoglobulin G

Identifiers

PMID24762744
PMCPMC3998937
OpenAlexW2147440419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.